Literature DB >> 11731090

Factor X activator from Vipera lebetina snake venom, molecular characterization and substrate specificity.

E Siigur1, K Tõnismägi, K Trummal, M Samel, H Vija, J Subbi, J Siigur.   

Abstract

Our studies of the venom from the Levantine viper Vipera lebetina have demonstrated the existence of both coagulants and anticoagulants of the hemostatic system in the same venom. We showed that V. lebetina venom contains factor X activator (VLFXA) and factor V activator, fibrinolytic enzymes. VLFXA was separated by gel filtration on Sephadex G-100 superfine and ion exchange chromatography on CM-cellulose and on TSK-DEAE (for HPLC) columns. VLFXA is a glycoprotein composed of a heavy chain (57.5 kDa) and two light chains (17.4 kDa and 14.5 kDa) linked by disulfide bonds. VLFXA has multiple molecular forms distinguished by their isoelectric points. The differences in their pI values may be caused by dissimilarities in the respective charged carbohydrate content or in the primary sequence of amino acids. We synthesized 6-9 amino acid residues containing peptides according to physiological cleavage regions of human factor X and human factor IX. The peptides (Asn-Asn-Leu-Thr-Arg-Ile-Val-Gly-Gly - factor X fragment, and Asn-Asp-Phe-Thr-Arg-Val-Val-Gly-Gly - factor IX fragment) were used as substrates for direct assay of VLFXA. Cleavage products of peptide hydrolysis and the molecular masses of cleavage products of human factor X were determined by MALDI-TOF MS. The MALDI-TOF MS was highly efficient for the recovery and identification of peptides released by VLFXA hydrolysis. We can conclude that VLFXA cleaves the Arg(52)-Ile(53) bond in the heavy chain of human factor X and the Arg(226)-Val(227) bond in human factor IX precursor. VLFXA could not activate prothrombin nor had any effect on fibrinogen, and it had no arginine esterase activity toward benzoylarginine ethyl ester.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11731090     DOI: 10.1016/s0304-4165(01)00206-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  cDNA cloning, expression and fibrin(ogen)olytic activity of two low-molecular weight snake venom metalloproteinases.

Authors:  Ying Jia; Sara Lucena; Esteban Cantu; Elda E Sánchez; John C Pérez
Journal:  Toxicon       Date:  2009-04-16       Impact factor: 3.033

2.  Comparative study of anticoagulant and procoagulant properties of 28 snake venoms from families Elapidae, Viperidae, and purified Russell's viper venom-factor X activator (RVV-X).

Authors:  Montamas Suntravat; Issarang Nuchprayoon; John C Pérez
Journal:  Toxicon       Date:  2010-09-15       Impact factor: 3.033

Review 3.  Biochemistry and toxicology of proteins and peptides purified from the venom of Vipera berus berus.

Authors:  Jüri Siigur; Ene Siigur
Journal:  Toxicon X       Date:  2022-06-12

4.  Pharmaco-modulations of induced edema and vascular permeability changes by Vipera lebetina venom: inflammatory mechanisms.

Authors:  Fatima Sebia-Amrane; Fatima Laraba-Djebari
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

5.  The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.

Authors:  Nalise Low Ah Kee; Jason Krause; Gregory L Blatch; Koji Muramoto; Kazuo Sakka; Makiko Sakka; Ryno J Naudé; Leona Wagner; Raik Wolf; Jens-Ulrich Rahfeld; Hans-Ulrich Demuth; Wojciech P Mielicki; Carminita L Frost
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

6.  Bioinformatics and multiepitope DNA immunization to design rational snake antivenom.

Authors:  Simon C Wagstaff; Gavin D Laing; R David G Theakston; Christina Papaspyridis; Robert A Harrison
Journal:  PLoS Med       Date:  2006-06       Impact factor: 11.069

7.  Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors.

Authors:  Abhinandan Chowdhury; Christina N Zdenek; Matthew R Lewin; Rebecca Carter; Tomaž Jagar; Erika Ostanek; Hannah Harjen; Matt Aldridge; Raul Soria; Grace Haw; Bryan G Fry
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

8.  Snake Venom Cytotoxins, Phospholipase A2s, and Zn2+-dependent Metalloproteinases: Mechanisms of Action and Pharmacological Relevance.

Authors:  Sardar E Gasanov; Ruben K Dagda; Eppie D Rael
Journal:  J Clin Toxicol       Date:  2014-01-25

Review 9.  ADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural Overview.

Authors:  Soichi Takeda
Journal:  Toxins (Basel)       Date:  2016-05-17       Impact factor: 4.546

Review 10.  Processing of Snake Venom Metalloproteinases: Generation of Toxin Diversity and Enzyme Inactivation.

Authors:  Ana M Moura-da-Silva; Michelle T Almeida; José A Portes-Junior; Carolina A Nicolau; Francisco Gomes-Neto; Richard H Valente
Journal:  Toxins (Basel)       Date:  2016-06-09       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.